Sildenafil Tablet, Film Coated
Product Images NDC 71335-1638

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71335-1638). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351638)

Sildenafil Citrate 20 mg tablet packaging label shows a white round tablet description by Bryant Ranch Prepack, Burbank, CA. The label compares this product to Revatio 20 mg tablet by Macleods Pharmaceuticals Limited. Storage instructions indicate room temperature between 20°-25°C (68°-77°F). The package contains 10 tablets.*

FDA Label Image

Figure-10 (Sildenafil Fig 10)

A forest plot illustrating the placebo-corrected change in 6-minute walk distance for Sildenafil 20 mg taken three times daily (TID) across various subgroups, including baseline walk distance, etiology, pulmonary hypertension criteria and therapeutic class, gender, age, mean pulmonary artery pressure (PAP), and pulmonary vascular resistance index (PVRI). The plot compares effect sizes with confidence intervals for each subgroup.*

FDA Label Image

Figure-11 (Sildenafil Fig 11)

A Kaplan-Meier survival curve chart showing the percentage without a clinically worsening event over days from randomization. The chart compares two groups labeled Placebo and Sildenafil, with percentage values on the vertical axis and days on the horizontal axis, indicating the progression and cumulative event-free survival over time.*

FDA Label Image

Fig-12 (Sildenafil Fig 12)

A line graph illustrating the mean change from baseline in meters over 12 weeks of study for Sildenafil at doses of 1 mg, 5 mg, and 20 mg, each taken three times daily (TID). The x-axis shows the weeks of study (Week 4, Week 8, Week 12), and the y-axis shows the change from baseline. Error bars represent the standard error for each treatment at each visit.*

FDA Label Image

Fig-6 (Sildenafil Fig 6)

A line graph depicting estimated cumulative mortality rate (%) over time in years, comparing three groups labeled as High dose, Medium dose, and Low dose. The graph includes the number of participants at risk for each group at various time points up to five years. The High dose group shows the highest mortality rate increase, followed by Medium dose, with the Low dose group showing the lowest cumulative mortality rate.*

FDA Label Image

Fig-8 (Sildenafil Fig 8)

A chart depicting fold change and 90% confidence intervals for various drugs interacting with sildenafil. The chart shows changes relative to the interacting drug alone and includes recommendations on dose adjustments for each drug, mostly indicating no dose adjustment, with exceptions for ritonavir and bosentan. The x-axis represents fold change, and the y-axis lists the interacting drugs.*

FDA Label Image

Figure-9 (Sildenafil Fig 9)

A line graph depicting change from baseline in meters over weeks 4, 8, and 12 of study. The x-axis shows weeks of study and the y-axis shows change from baseline in meters. Four groups are compared: Placebo, Sildenafil 20mg TID, Sildenafil 40mg TID, and Sildenafil 80mg TID, with data points and error bars illustrating variability.*

FDA Label Image

Figure-7 (Sildenafil Figure 7)

A chart depicting the fold change and 90% confidence interval for AUC and Cmax of Sildenafil when administered with various interacting drugs. The x-axis shows change relative to Sildenafil alone, with values around 1 indicating no change. Recommendations on dose adjustment for each interacting drug are listed: most show no dose adjustment needed, except Ritonavir where coadministration is not recommended.*

FDA Label Image

Str (Sildenafil Str)

Chemical structure diagram of Sildenafil, illustrating its molecular composition including rings, carbon chains, and functional groups such as sulfonamide and carboxyl groups, consistent with the active ingredient in the Sildenafil 20 mg tablet.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.